Erythropoietin (EPO) to Protect Renal Function After Cardiac Surgery (EPRICS)

Region Skane

Status and phase: Completed; Phase 2

Conditions: Kidney Failure; Renal Failure

Treatments: Drug: Erythropoietin zeta; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT01423955

2011-001673-70

Details and patient eligibility

About

The purpose of this study is to evaluate the potential of erythropoietin in reducing risk and degree of acute kidney injury after cardiac surgery.

Full description

Acute kidney injury is a common complication after cardiac surgery and is associated with decreased long-term survival.

Several experimental and animal studies have showed cytoprotective, preconditioning and anti-apoptotic effects of high dose erythropoietin. Clinical studies in human have also suggested that high dose erythropoietin has preconditioning effects against injury after ischemia and reperfusion on different organs in human, such as brain, heart, liver, and kidneys.

Administration of Epo in high doses in conjunction with cardiac surgery has shown to be safe with no direct side-effects.

The investigators therefore hypothesize that a preconditioning effect of erythropoietin before cardiac surgery can reduce the level of renal dysfunction after surgery in a group with preoperative renal impairment.

Enrollment: 75 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• The patient is scheduled for non-emergent CABG surgery.
• CyC eGFR or MDRD eGFR < 60 ml/min.
• The patient has given his/her written consent to participate

Exclusion criteria

• The patient has an uncontrolled hypertension.
• Hypersensitivity to the active drug.
• The patient is pregnant or is a fertile woman (<50 years).
• The patient has been treated with Erythropoietin within 4 weeks prior to the surgery.
• Preoperative CyC eGFR or MDRD eGFR is < 15, or the patient is treated with dialysis.
• The patient has a known malignancy.
• The patient is planned for Off-pump CABG surgery.
• The patient is included in other ongoing clinical trial. Yes / No
• Clinically judgment by the investigator that the patient should not participate in the study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

75 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.

Treatment:

Drug: Placebo

Erythropoietin

Experimental group

Description:

• Active substance: Erythropoietin zeta with the ATC-code: B03XA01. The drug is a Clear colorless solution for injection. The active substance will be diluted with NaCl 9mg/ml to a to a concentration of 2000 U/ml. A dose of 400U/kg will be prepared and marked before the operation. The drug will be administrated after the anesthesia induction and before the start of surgery.

Treatment:

Drug: Erythropoietin zeta